Extramedullary Relapse Of Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation -Single Center Experience

Lin Ge,XiaoWen Tang,Fan Ye,Aining Sun,Changgeng Ruan,Wu Depei

DOI: https://doi.org/10.1182/blood.V120.21.4473.4473

IF: 20.3

2012-01-01

Blood

Abstract:Abstract 4473

What problem does this paper attempt to address?

P1383: Extramedullary Relapse Of Acute Myeloid Leukemia And Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation - A Single-Center Experience

F. Vasconcelos,D. Rochate,E. Couto,P. Coelho,L. Leite,R. Branca Ferreira,C. Pinho Vaz,A. Campos

DOI: https://doi.org/10.1097/01.hs9.0000848392.51857.b3

2022-06-25

HemaSphere

Abstract:Background: Acute leukemia relapse after allogeneic hematopoietic cell transplant (allo-HCT) is challenging. Allo-HCT is a potentially curative treatment for acute myeloid leukemia (AML) and Acute lymphoblastic leukemia (ALL). Extramedullary relapse (EMR) can occur in various extramedullary tissues such as the central nervous system (CNS), breast, bone, testis, and skin, and data on EMR after allo-HCT is limited.
Clinical Characteristics and Outcome of Isolated Extramedullary Relapse in Acute Leukemia Following Allogeneic Stem Cell Transplantation: A Single Institutional Analysis

Jimin Shi,Xiaojian Meng,Yamin Tan,Xiaoli Zhu,Gaofeng Zheng,Jingsong He,Weiyan Zheng,Wanzhuo Xie,Li,Xiujin Ye,Jie Zhang,Maofang Lin,He Huang

DOI: https://doi.org/10.1182/blood.v120.21.4211.4211

IF: 20.3

2012-01-01

Blood

Abstract:Abstract Abstract 4211 Isolated extramedullary relapse (EMR) of acute leukemia (AL) is a rare occurrence although it appears to be more common following allogeneic stem cell transplantation (allo-SCT). To characterize what has been observed in isolated EMR, we investigated a total of 287 consecutive AL patients (144 acute myeloid leukemia, 138 acute lymphocytic leukemia and 5 acute mixed lineage leukemia) who underwent allo-SCT. Forty-seven (16.4%) patients experienced relapse after allo-SCT. 12 cases (4.2%) experienced relapse of extramedullary sites without concomitant bone marrow involvement. Isolated EMR accounted for 25.5% of the overall initial relapse. The time to relapse after allo-SCT was longer in the extramedullary sites than in the marrow (median, 10 months vs. 5.5 months, P<0.05,). Sites of EMR varied widely including central nervous system, skin, bone, pelvis and breasts. The variables considered for univariate analysis included donor gender, age, primary disease, disease status, cytogenetics/molecular abnormalities, preconditioning regimen, donor type, HLA match, aGVHD and cGVHD. The variables that showed significant correlation with isolated EMR were the cytogenetics abnormalities at diagnosis. The prognosis for patients who develop EMR remained poor but was relatively better than that after bone marrow (BM) relapse (overall survival, 10 vs. 18 months, P<0.05). Compared with local or single therapy, patients treated with systemic in combination with local treatment could yield favorable prognosis. Three patients survived 63, 55 and 49 months after transplant respectively, of whom two received DLI with subsequent chemotherapy and (or) irradiation and one had surgery with subsequent chemotherapy. In conclusion, we observed a significant number of isolated EMR of AL after allo-SCT and intensive approaches combined of local and systemic therapy can produce favorable response which may cure a percentage of these patients. Disclosures: No relevant conflicts of interest to declare.
Extramedullary Relapse of Acute Adult Leukemia Following Allogeneic Stem Cell Transplantation:10 Cases Analysis.

Jimin Shi,Yi Luo,Yamin Tan,Xiaoli Zhu,Jingsong He,Weiyan Zheng,Wanzhuo Xie,Li Li,Xiujin Ye,Jie Zhang,Zhen Cai,Maofang Lin,He Huang

DOI: https://doi.org/10.1182/blood.v116.21.4513.4513

IF: 20.3

2010-01-01

Blood

Abstract:Abstract Abstract 4513 Background: Up to date, the knowledge concerning the predisposing factors, pathogenesis and mechanisms of isolated extramedullary relapse (EMR) of acute leuekmia (AL) has not been well elucidated. Method: We retrospectively analyzed 215 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our center from 1998 to 2006. All of them were adult AL patients (110 acute myeloid leukemia (AML), 102 acute lymphocytic leukemia (ALL) and 3 acute mixed lineage leukemia). 10 cases (4.7%) experienced relapse of extramedullary sites. Among these 10 patients, there were four male and six female patients with a median age of 25 years (range, 22–38 years). Six patients were AML and four patients were ALL. The median interval from diagnosis to transplantation was 9 months (range, 6–15 months). Five patients had cytogenetics or molecular abnormalities. All the patients were in first CR. All the donors were HLA-identical matched (5 siblings and 5 unrelated donor). Conditioning regimen included BU and CY without total body irradiation (TBI). Graft-versus-host disease (GVHD) prophylaxis is consisted of cyclosporin A, a short-term methotrexate and mycophenolate mofetil. Result: Ten patients experienced isolated EMR at a median of 10 months (range, 3–28months) after allo-HSCT. Sites of EMR varied widely and included CNS (leptomeninges, brain, retro-orbital tissue and paraspinal tissue), skin, bone, pelvis and breasts. Five patients experienced two or more sites of EMR. The most frequently involved in relapse sites were CNS (4 patients) and skin (3 patients). Three patients subsequently developed bone marrow relapse, two patients in 2 and 3 months after the initial EMR and the third patient in 3 months after the second onset of EMR. The remaining seven patients did not develop bone marrow involvement at a follow-up ranged from 3 to 8 months after the initial EMR. Three patients received donor lymphocytes infusion (DLI) combined with chemotherapy and (or) irradiation, two patients achieved CR and remain free of disease for 25 and 32 months after transplant whereas one died due to the second EMR and the following marrow relapse. Two patients received local surgery in combination with radiotherapy or chemotherapy and both remain free of disease for 7 and 18 months post transplant. Among five patients who were only treated with local irradiation or chemotherapy or supportive care, four died from progressive disease. Conclusion: The prognosis of EMR is generally considered to be unfavorable. An intensified regimen combined of local interventions with systemic chemotherapy may be benefit for patients. Disclosures: No relevant conflicts of interest to declare.
Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

Xu Xiao

2001-01-01

Abstract:Objective:To explore the hematopoietic reconstitution,the incidence of GVHD and the efficacy of allogeneic peripheral blood stem cell transplantation (allo PBSCT).Methods:The data of 13 leukemia patients undergoing allo PBSCT were retrospectively analyzed,including 12 patients receiving peripheral blood stem cell(PBSC) from HLA matched sibling donors,and the remaining one from haploidentical related donor.The BU CY2 was used as conditioning regimen.Cyclosporine A and either methotrexate or methylprednisolone were administered to prevent acute GVHD.PBSC was mobilized with G CSF.Results:All patients were grafted with ANC0.5×10 9/L at a median of 13 days and BPC20×10 9/L at a median of 12 days.Acute GVHD occurred in 4 of 12 patients receiving PBSC from HLA matched sibling donors,one receiving PBSC from haploidentical related donor developed grade Ⅳ acute GVHD.Chronic GVHD occurred in 6 patients.Two patients died of grade Ⅳ acute GVHD and 3 died of relapse.Conclusion:Allo PBSCT can repidly reconstitute hematopoiesis,and the incidence of acute GVHD was comparable with that in allo BMT,but the incidence of chronic GVHD was increased by allo PBSCT as compared with allo BMT.
Clinical characteristics and outcome of isolated extramedullary relapse in acute leukemia after allogeneic stem cell transplantation: a single-center analysis.

Ji-Min Shi,Xiao-Jian Meng,Yi Luo,Ya-Min Tan,Xiao-Li Zhu,Gao-Feng Zheng,Jing-Song He,Wei-Yan Zheng,Wan-Zhuo Xie,Li Li,Xiu-Jin Ye,Jie Zhang,Zhen Cai,Mao-Fang Lin,He Huang

DOI: https://doi.org/10.1016/j.leukres.2012.12.002

IF: 3.715

2013-01-01

Leukemia Research

Abstract:Isolated extramedullary relapse (EMR) of acute leukemia (AL) is a rare occurrence. However, it appears to be more common after allogeneic stem cell transplantation (allo-SCT). To characterize what has been observed in isolated EMR, we investigated 287 consecutive AL patients (144 acute myeloid leukemia; 138 acute lymphocytic leukemia; 5 acute mixed-lineage leukemia) who underwent allo-SCT. Twelve cases experienced relapse at extramedullary sites without concomitant involvement of the bone marrow (BM). The onset to relapse after allo-SCT was longer in extramedullary sites than in the BM (median, 10 months versus 5.5 months). EMR sites varied widely and included the central nervous system, skin, bone, pelvis and breasts. Univariate analysis demonstrated that cytogenetic abnormalities were correlated significantly with the onset of isolated EMR (P=0.001). The prognosis for patients who develop EMR remained poor but was relatively better than that after BM relapse (overall survival, 10 versus 18 months). Compared with local or single therapy, patients treated with systemic treatment in combination with local treatment could yield a favorable prognosis. In conclusion, we observed a significant number of isolated cases of EMR in AL patients after allo-SCT, cytogenetic abnormalities were correlated significantly with the onset of isolated EMR. We found that intensive approaches combining local and systemic therapy could produce favorable responses which may cure a proportion of these patients.
Haploidentical Allogeneic Hematopoietic Cell Transplantation As Salvage Therapy for Engraftment Failure after Unrelated and Autologous Cell Transplantation.

Yamin Tan,Huarui Fu,Yi Luo,Xiujin Ye,Li,Yanlong Zheng,Jimin Shi,Jie Sun,Liqun Zhou,Haowen Xiao,Yongxian Hu,He Huang

DOI: https://doi.org/10.1182/blood.v116.21.4529.4529

IF: 20.3

2010-01-01

Blood

Abstract:Abstract Abstract 4529 Engraftment failure is a rare but life-threatening complication of hematopoietic stem cell transplantation. The treatment of this condition is often challenging. We firstly reported haploidentical donor stem cells transplantation resulted in hematological reconstitution and long-time disease-free survival in a patient who developed engraftment failure after unrelated donor allogeneic stem cell transplantation and failure rescue treatment by re-infusion of autologous “back-up” stem cells. The 39-years-old male patient with acute myeloid leukemia(AML)-M2a achieved complete remission (CR) after one course of induction chemotherapy. He entered a lasting CR with 7 courses post-remission consolidation therapy and decided to receive unrelated donor allogeniec stem cell transplantation. In case of engraftment failure after allo-HSCT, autologous “back-up” cells were harvested after the last course chemotherapy (IDA 15 mg on days 1–2, 10 mg on day 3, Ara-c 300 mg on days 1–3, 200 mg on day 4), and mobilized with G-CSF 5 mg/kg/day for 5 days. The “back-up” cells consisting of 9.94×106/kg CD34+ cells were cryopreservated in liquid nitrogen. Fifteen months after de novo AML, the patient received a myeloablative conditioning regimen of busulfan and cyclophosphamide (busulfan 3.2 mg/kg/day on days -7 to -4, and cyclophosphamide 60 mg/kg/day on days -3 to -2), and an infusion of unrelated allogeneic peripheral stem cells from the Chinese Marrow Donor Program with a HLA-Cw allele mismatch on day 0. The graft contained 11.07×108/kg nucleated cells and 6.35×106/kg CD34+ cells. Pancytopenia was continuously observed during 28 days after transplantation and short tandem repeat-polymerase chain reaction (STR-PCR) analysis showed no donor chimera. As a rescue attempt for graft failure, cryopreservated autologous cells were re-infused on day +28. Unfortunately, pancytopenia was still continuously observed during 23 days after re-infused of “back-up” cells(51 days after unrelated transplantation), and bone marrow examination revealed severe bone marrow hypoplasia. On day +57 and +58 after unrelated transplantation, bone marrow cells containing 2.1×106/kg CD34+ stem cells and peripheral blood cells containing 2.81×106/kg CD34+ stem cells from a haploidentical donor sister (HLA matched in 5/10 alleles by high-resolution genotyping) were infused respectively after reduced-intensity conditioning with fludarabine and ATG (fludarabine 30mg/m2/d on day -5 to -1, ATG 100mg/d on day -4 to -1). Absolute neutrophil count >0.5×109/L was documented on day 12 after haploidentical transplantation. He achieved platelets count >20×109/L on day 28 after haploidentical transplantation. Twenty-nine days after haploidentical transplantation, bone marrow examination showed reconstitution and STR-PCR analysis indicated complete donor chimera. No grades III -IV aGVHD, extensive chronic GVHD, and severe infection after transplantation were observed. Recurrent bone marrow aspiration examinations showed the patient had been in CR. The patient remained alive during a 18-month follow-up after haploidentical transplantation. Our experience suggests that combined haploidentical donor BM and PBSC transplantation after Flu- and ATG-based conditioning could provide an effective therapeutic strategy for engraftment failure after unrelated allo-HSCT in adult patients. Considering the accessibility of haploidentical donors, haploidentical transplantation has the potential to act as a first-line choice for salvage therapy. Disclosures: No relevant conflicts of interest to declare.
Clinical Analysis of Extramedullary Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia

YANG Zhen-ling,ZHU Kang-er,ZHANG Tao,CHEN Jie

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2010.11.010

2010-01-01

Abstract:Objective To investigate the incidence, risk factors, treatment and clinical outcome of extramedullary EM) relapse following allogeneic hematopoietic stem cell transplantation (alloHSCT), and explore the possible pathogenesis. Methods We retrospectively analyzed the medical records of 164 patients who underwent allogeneic HSCT. The 10 clinical parameters were selected for Cox univariate analysis: gender, age, underlying disease, donor type, disease status at transplant,HLA disparity, acute GVHD, chronic GVHD, EM involvement prior to transplantation and conditioning regimen. Factors that were significant at the 0. 10 level on univariate analysis were evaluated by multivariate analysis using a Cox regression. The therapeutic options for EM relapse included local radiation, surgical removal, chemotherapy, donor lymphocyte infusion (DLI), second HSCT. Results 164 recipients had sustained engraftment. EM relapse occurred in 9 patients(5.5 %), with a median time to EM relapse of 7.5 months (2.3 to 42.6 months). Ninety-fourpatients (57. 3 % ) developed acute GVHD and 83 (50. 6 % ) chronic GVHD respectively. Four patients died of EM relapse. The following factors were associated with an increased risk of EM relapse by univariate analysis: gender, donor type, disease status at transplant, chronic GVHD, EM involvement prior to transplantation. Only advanced stage of the disease (P＜ 0. 05), absence of chronic GVHD (P＜0. 01) and EM involvement prior to transplantation (P＜0. 01) were identified as being significantly associated with the occurrence of EM relapse by multivariate analysis using a Cox regression. Conclusion Many factors may be involved in the pathogenic mechanism of EM relapse,and among them, immune escape might play a major role. Advanced stage of the disease, absence ofchronic GVHD and EM involvement prior to transplantation were independently associated with an increased risk of EM relapse. EM relapse frequently followed by bone marrow involvement has poor prognosis, and therefore, prevention of leukemic cells spreading from EM sites to bone marrow is vital for long-term survival.
Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes.

Xiao-Dong Mo,Jun Kong,Ting Zhao,Lan-Ping Xu,Xiao-Hui Zhang,Dai-Hong Liu,Yu Wang,Huan Chen,Chen-Hua Yan,Yu-Hong Chen,Wei Han,Feng-Rong Wang,Jing-Zhi Wang,Kai-Yan Liu,Xiao-Jun Huang

DOI: https://doi.org/10.1016/j.bbmt.2014.08.023

2014-01-01

Abstract:We examined the incidence, risk factors, treatment, and clinical outcomes of extramedullary relapse (EMR) in 961 acute leukemia patients undergoing HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) between 2002 and 2013. Multiple control subjects were selected at random from the same cohort and matched to EMR cases for diagnosis, disease status at HSCT, age at the time of the HSCT, and year of HSCT. Forty patients exhibited EMR, with a median time to EMR of 207 days. The cumulative incidence of EMR was 4.0% at 3 years, and the incidence was higher in acute lymphoblastic leukemia patients compared with acute myeloid leukemia patients (5.6% versus 2.4%). In the multivariate analysis, non-complete remission (CR) status at HSCT (hazard ratio [HR] = 4.6; P = .018) and non-chronic graft-versus-host disease after HSCT (HR = 3.2; P < .001) were the independent risk factors for EMR after haplo-HSCT. Twenty-seven patients received combination treatments, and the proportion of patients who achieved CR was higher than those who received single treatment. Multifocal involvement at EMR (HR = 2.7; P = .024) and non-CR after EMR treatments (HR = 4.6; P < .001) were the independent risk factors for poor survival rates among EMR patients. We found that graft-versus-leukemia effect may help to prevent EMR after haplo-HSCT.
Extramedullary Relapse Of Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Different Characteristics Between Acute Myeloid Leukemia And Acute Lymphoblastic Leukemia

L. Ge,F. Ye,X. Mao,J. Chen,A. Sun,X. Zhu,H. Qiu,Z. Jin,M. Miao,C. Fu,X. Ma,F. Chen,S. Xue,C. Ruan,D. Wu,X. Tang

DOI: https://doi.org/10.1016/j.bbmt.2014.03.030

2014-01-01

Biology of Blood and Marrow Transplantation

Abstract:Extramedullary relapse (EMR) of acute leukemia (AL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a contributor to post-transplantation mortality and remains poorly understood, especially the different characteristics of EMR in patients with acute myelogenous leukemia (AML) and those with acute lymphoblastic leukemia (ALL). To investigate the incidence, risk factors, and clinical outcomes of EMR for AML and ALL, we performed a retrospective analysis of 362 patients with AL who underwent allo-HSCT at the First affiliated Hospital of Soochow University between January 2001 and March 2012. Compared with patients with AML, those with ALL had a higher incidence of EMR (12.9% versus 4.6%; P = .009). The most common site of EMR was the central nervous system, especially in the ALL group. Multivariate analyses identified the leading risk factors for EMR in the patients with AML as advanced disease status at HSCT, hyperleukocytosis at diagnosis, history of extramedullary leukemia before HSCT, and a total body irradiation–based conditioning regimen, and the top risk factors for EMR in the patients with ALL as hyperleukocytosis at diagnosis, adverse cytogenetics, and transfusion of peripheral blood stem cells. The prognosis for EMR of AL is poor, and treatment options are very limited; however, the estimated 3-year overall survival (OS) was significantly lower in patients with AML compared with those with ALL (0 versus 18.5%; P = .000). The characteristics of post–allo-HSCT EMR differed between the patients with AML and those with ALL, possibly suggesting different pathogenetic mechanisms for EMR of AML and EMR of ALL after allo-HSCT; further investigation is needed.
Extraordinarily Elevated CD33 Expression in CD56+CD3– Cells in the Bone Marrow of a Patient with Relapsed Acute Myeloid Leukemia: a Case Report

Dongyao Wang,Liangquan Geng,Huilan Liu,Yongjun Fang,Zimin Sun

DOI: https://doi.org/10.21037/tcr-21-733

2021-01-01

Translational Cancer Research

Abstract:Based on genetic risk allogeneic stem cell transplantation (allo-SCT) is the only curative treatment for some forms of acute myeloid leukemia (AML). However, post-transplantation relapse remains a frequent cause of transplantation failure. Natural killer (NK) cells and CD8+ T cells are important effector lymphocytes with pivotal roles in tumor surveillance and anti-tumor immune response. In this study, a 14-year-old female patient with AML was treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT). Bone marrow relapse was found 6 months later. Thereafter, the patient was treated with DAE (daunorubicin, cytosine arabinoside, and etoposide), followed by IAE (idarubicin, cytosine arabinoside, and etoposide), and then MA (mitoxantrone and cytosine arabinoside) regimens. A series of experiments including Wright-Giemsa stain analyses, cytogenetic analysis and flow cytometry were conducted to investigate the characteristic of the patient. Although there was a short remission after the DAE regimen, the patient experienced another relapse after finishing the MA regimen. The CD56+CD3‒ cells in the bone marrow showed severely impaired activation and anti-tumor function, while extraordinarily increased CD33 expression. Moreover, the proportion of multifunctional effector CD8+ T cells remained stable, though they had high PD-1 expression. These findings revealed the dysfunction of abnormal CD56+CD3- cells with high CD33 expression, which might be targetable and related to the relapsed/refractory AML after allo-SCT.
Acute Promyelocytic Leukemia With Flt3-Tkd And Wt1 Mutations Relapsing In A Testicle And Followed By Systemic Relapse

Xing-li Zou,Ke Zeng,Li-ping Xie,Lin Wang,Min Chen,Ting Liu,Ting Niu

DOI: https://doi.org/10.1159/000351054

2013-01-01

Acta Haematologica

Abstract:Extramedullary relapse is a rare phenomenon in patients with acute promyelocytic leukemia (APL), especially that derived from urogenital systems like the testicles. In this report, we describe an APL patient who had received standard induction/maintenance therapy resulting in durable remission for 4.5 years, when he presented with a unilateral testicular mass confirmed as myeloid sarcoma; this was followed by systemic relapse of APL. Retrospective analysis of the involved blood and bone marrow samples at the time of the initial diagnosis revealed a rare point mutation of FLT3-TKD and a novel mutation of WT1. These mutations were detected recurrently throughout the course of the disease. After reinduction therapy with arsenic trioxide and all-trans retinoic acid combined with daunorubicin, complete hematological remission was achieved for the ensuing salvage allogeneic hematopoietic stem cell transplant. Copyright (C) 2013 S. Karger AG, Basel
High Risk Factors of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-Hsct) for Leukemia.

Jia Chen,Feng Chen,Wu Depei,Aining Sun,Huiying Qiu,Zhengming Jin,Xiaowen Tang,Miao,Chengcheng Fu,Guangsheng He

DOI: https://doi.org/10.1182/blood.v114.22.4345.4345

IF: 20.3

2009-01-01

Blood

Abstract:Abstract Abstract 4345 Object To screen the high risk factors of relapse after allo-HSCT in acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) respectively, then to compare the contribution to relapse of each risk factor and explore the mechanisms which the factors take part in. Furthermore, to discuss the subsequent surveillance and treatment strategy after transplantation. Method This is a retrospective study of single center experience. We conduct 262 evaluable cases of leukemia which accepted allo-HSCT between the November, 2001 and the December, 2008, with 69 cases in ALL, 90 cases in AML and 103 cases in CML. Cox proportional hazard regression model is applied in single and multiple analysis to screen the high risk factors. Donor lymphocyte infusions(DLI) were administrated in 18 patients who relapsed after transplantation, and we describe the characteristics of this approach. Results The risk factors which affect relapse significantly are: ALL: Cytogenetic risk classification, the cycles of initial induction chemotherapy; AML: Cytogenetic risk classification, minimal residual disease (MRD) level before transplant, reconstitution of WBC, CD4+/CD8+ lymphocyte ratio in the graft; CML: disease stage before transplant. 9 of the 18 patients who had a lower tumor load benefited from the DLI. Conclusion Cytogenetic risk classification is the most relevant predictor of relapse after transplantation. DLI hold great promise to overcome the barrier of relapse, especially for patients with lower disease burden. Disclosures: No relevant conflicts of interest to declare.
Comparison of clinical features and treatments of extramedullary relapse after haploidentical and matched sibling donor allogeneic hematopoietic stem cell transplantation in acute leukemia patients

Fengmei Zheng,Jun Kong,Ting Zhao,Xiaohui Zhang,Lanping Xu,Yu Wang,Chenhua Yan,Huan Chen,Yuhong Chen,Wei Han,Fengrong Wang,Jingzhi Wang,Kaiyan Liu,Xiaojun Huang,Xiaodong Mo

DOI: https://doi.org/10.3760/cma.j.issn.2096-5400.2018.03.006

2018-01-01

Abstract:Objective To compare the clinical features of extramedullary relapse (EMR) of acute leukemia after haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (HSCT) and matched sibling donor (MSD) HSCT.Methods Medical records of acute leukemia patients treated with HSCT including 48 HID-HSCT patients and 42 MSD patients from January 2001 to December 2015 were analyzed retrospectively.Results The most common site of EMR in HID group was central nervous system (56.2％) and the most common sites of EMR in MSD group were central nervous system (38.1％) and skin/soft tissues (38.1％).The most common sites of EMR after HSCT in group HID and group MSD were central nervous system and skin/soft tissues.Patients in group MSD were more likely to involve multiple extramedullary sites than that in group HID (33.3％ vs.10.4％,x2 =7.064,P =0.010),and patients in group MSD were more likely to involve site of skin/soft tissue.The EMR time of HID group was 241.5(10～2 856) days,which was earlier than that of MSD group [302 (35～1 532) days,Z=2.091,P=0.037].The rates of complete remission (CR) of EMR treatments in the two groups were 56.2％ vs.69％ respectively (x2=1.561,P =0.277).The 2-year progressionrelated mortality (PRM) were (45.4± 8.2) ％ and (37± 8.1) ％ respectively (x2 =1.002,P =0.317).The 2-year treatment-related mortality (TRM) after EMR were (15 ± 5.8)％ vs.(10.3±5.0)％respectively (x2 =0.098,P=0.754).The 2-year overall survival (OS) after EMR were (39.6±8.0)％vs.(52.7±8.2)％,respectively (x2=1.527,P=0.217).There were no differences in PRM,TRM and OS between the two groups.The 2-year OS after EMR in the combination treatment group was higher than that in themonotherapygroup[(53±6.7)％ vs.(31.9±11.2)％,x2=7.966,P=0.005],especially for patients receiving MSD-HSCT [(63±8.9)％ vs.(14.6± 13.3)％,x2 =6.542,P=0.011].Conclusions The most common sites of EMR after allo-HSCT were central nervous system and skin/soft tissues.The skin/soft tissues involvement was more common in MSD-HSCT recipients.The patients in MSD group were more likely to involve multiple systems after allo-HSCT,and this group of patients might be more likely to benefit from the combination treatment.For patients with EMR after HID transplant,further studies will be needed to improve prognosis.
[Extramedullary relapse in the external auditory canal in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid and autologous peripheral blood stem cell transplantation]

M Yagita,R Onishi,N Yamagata,C Shimazaki,H Kudoh,M Kobayashi,K Hikiji,Y Konaka

Abstract:A 41-year-old man was given a diagnosis with of acute promyelocytic leukemia (APL) in August 1994. A chromosome analysis showed 46, XY, t(15; 17) and 47, XY, idem, +8 at that time. Because initial induction chemotherapy (BHAC-DMP) has not been successful, the patient was given 45 mg/m2 of all-trans retinoic acid (ATRA) and achieved complete remission (CR) after 26 days on this regimen. Following intensified chemotherapy, he received an autologous peripheral blood stem cell transplant (PBSCT) with high-dose busulfan and cyclophosphamide in April 1995. Competitive RT-PCR for PML-RAR alpha mRNA did not find any of APL cells in the collected stem-cell fraction. Although the patient remained in CR without therapy, a myeloblastoma was found in his left external auditory canal in August 1996. Recurrence in bone marrow, moreover, was discovered the following month. A chromosome analysis of bone marrow cells showed 47, XY, t(15; 17), +8 at this time. Thus, the extramedullary relapse developed after autologous PBSCT. This case provides information linking ATRA to the development of extramedullary relapse in patients with APL.
Secondary Donor-Derived CD19 CAR-T Therapy is Safe and Efficacious in Acute Lymphoblastic Leukemia with Extramedullary Relapse after First Autologous CAR-T Therapy

Kong Delin,Yang Tingting,Geng Jia,Jing Ruirui,Zhang Qiqi,Wei Guoqing,Huang He,Hu Yongxian

DOI: https://doi.org/10.1631/jzus.b2200128

2022-01-01

Abstract:Despite the advancement of treatments, adults with relapsed/refractory (R/R) B-lineage acute lym-phoblastic leukemia (B-ALL) have poor prognosis, with an expected five-year overall survival (OS) rate of 10％?20％(Nguyen et al., 2008;Oriol et al., 2010). Extramedullary relapse of B-ALL is regarded as a high-risk factor generally associated with poor survival, occurring in about 15％to 20％of all relapsed patients (Ding et al., 2017; Sun et al., 2018). The central nervous system (CNS) and the testes are the most common sites of extramedullary relapse of B-ALL. In addition, extramedullary leukemia can appear in the skin, eyes, breasts, bones, muscles, and abdominal organs. The prognosis of relapsed extramedullary B-ALL after allogeneic hematopoietic stem cell trans-plantation (allo-HSCT) is extremely poor (Spyridonidis et al., 2012; Dahlberg et al., 2019). Conventional chemotherapy or radiation is often ineffective in such patients. At present, there are no optimal treatment strategies for treating extramedullary leukemia after allo-HSCT.
Prophylaxis and Treatment of Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Runzhe Chen,Jos L Campbell,Baoan Chen

DOI: https://doi.org/10.2147/ott.s78567

IF: 4

2015-01-01

OncoTargets and Therapy

Abstract:Relapse of acute lymphoblastic leukemia remains a major cause of death in patients following allogeneic hematopoietic stem cell transplantation. Several factors may affect the concurrence and outcome of relapse, which include graft-versus-host disease, minimal residual disease or intrinsic factors of the disease, and transplantation characteristics. The mainstay of relapse prevention and treatment is donor leukocyte infusions, targeted therapies, second transplantation, and other novel therapies. In this review, we mainly focus on addressing the impact of graft-versus-host disease on relapse and the prophylaxis and treatment of acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. We also make recommendations for critical strategies to prevent relapse after transplantation and challenges that must be addressed to ensure success.
[Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia]

Shan-Dong Tao,Li-Xiao Song,Yuan Deng,Yue Chen,Xin Zhang,Bang-He Ding,Chun-Ling Wang,Liang Yu

DOI: https://doi.org/10.19746/j.cnki.issn.1009-2137.2023.03.010

Abstract:Objective: To observe the efficacy and safety of CLAE intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed/refractory acute leukemia (R/R AL). Methods: CLAE regimen [cladribine 5 mg/(m2·d), d 1-5; cytarabine 1.5 g/(m2·d), d 1-5; etoposide 100 mg/(m2·d), d 3-5] followed by allo-HSCT was used to treat 3 R/R AL patients. The patients received CLAE chemotherapy in relapsed or refractory status and underwent bone marrow puncture to judge myelodysplastic state. After an interval of 3 to 5 days, followed by preconditioning regimen for allo-HSCT [fludarabine 30 mg/(m2·d), d -7 to d -3; busulfan 0.8 mg/kg q6h, d -6 to d -3 or d -5 to d -2. If the bone marrow hyperplasia was not active and the blasts were less than 10%, busulfan should be used for 3 days. If the bone marrow hyperplasia was active and the blasts were more than 10%, busulfan should be used for 4 days]. Cyclosporin A, mycophenolate mofetil and short-term methotrexate were used for graft-versus-host disease (GVHD) prevention. After transplantation, the status of minimal residual disease (MRD) and bone marrow chimerism were regularly monitored in all 3 patients, and demethylation drugs or dasatinib were used to prevent recurrence 3 months after transplantation. Results: 2 patients with t(11;19) translocation and relapse/refractory acute myeloid leukemia recurred within 6 months after induction of remission, and received intensive chemotherapy with CLAE regimen followed by haploidentical allo-HSCT and unrelated donor allo-HSCT, respectively. The two patients both relapsed 6 months after transplantation, then achieved complete remission by donor lymphocyte infusion, interferon, interleukin-2 and other methods, and disease-free survival was 2 years after transplantation. The other patient was chronic myelogenous leukemia who developed acute lymphoblastic leukemia during oral administration of tyrosine kinase inhibitor, accompanied by T315I and E255K mutations in ABL1 kinase region and additional chromosomal abnormalities. After morphological remission by induction chemotherapy, central nervous system leukemia was complicated. Intensive chemotherapy with CLAE regimen followed by sibling allo-HSCT was performed in the positive state of MRD. The patient relapsed 3 months after transplantation, and achieved remission after chimeric antigen receptor T-cell (CAR-T) therapy, however, he died 5 months after transplantation because of severe cytokine release syndrome (CRS) and GVHD. Conclusion: CLAE regimen followed by allo-HSCT may be an effective salvage treatment option for R/R AL patients to prolong the overall survival.
HLA-Mismatched Stem-Cell Microtransplantation As Postremission Therapy for Acute Myeloid Leukemia: Long-Term Follow-Up

Mei Guo,Kai-Xun Hu,Guang-Xian Liu,Chang-Lin Yu,Jian-Hui Qiao,Qi-Yun Sun,Jun-Xiao Qiao,Zheng Dong,Wan-Jun Sun,Xue-Dong Sun,Hong-Li Zuo,Qiu-Hong Man,Zhi-Qing Liu,Tie-Qiang Liu,Hong-Xia Zhao,Ya-Jing Huang,Li Wei,Bing Liu,Juan Wang,Xu-Liang Shen,Hui-Sheng Ai

DOI: https://doi.org/10.1200/jco.2012.42.0281

IF: 45.3

2012-11-20

Journal of Clinical Oncology

Abstract:Purpose Despite best current therapies, approximately half of patients with acute myeloid leukemia in first complete remission (AML-CR1) with no HLA-identical donors experience relapse. Whether HLA-mismatched stem-cell microtransplantation as a novel postremission therapy in these patients will improve survival and avoid graft-versus-host disease (GVHD) is still unknown. Patients and Methods One hundred one patients with AML-CR1 (9 to 65 years old) from four treatment centers received programmed infusions of G-CSF–mobilized HLA-mismatched donor peripheral-blood stem cells after each of three cycles of high-dose cytarabine conditioning without GVHD prophylaxis. Donor chimerism and microchimerism and WT1 + CD8 + T cells were analyzed. Results The 6-year leukemia-free survival (LFS) and overall survival (OS) rates were 84.4% and 89.5%, respectively, in the low-risk group, which were similar to the rates in the intermediate-risk group (59.2% and 65.2%, respectively; P = .272 and P = .308). The 6-year LFS and OS were 76.4% and 82.1%, respectively, in patients who received a high dose of donor CD3 + T cells (≥ 1.1 × 10 8 /kg) in each infusion, which were significantly higher than the LFS and OS in patients who received a lower dose (< 1.1 × 10 8 /kg) of donor CD3 + T cells (49.5% and 55.3%, respectively; P = .091 and P = .041). No GVHD was observed in any of the patients. Donor microchimerism (2 to 1,020 days) was detected in 20 of the 23 female patients who were available for Y chromosome analysis. A significant increase in WT1 + CD8 + T cells (from 0.2% to 4.56%) was observed in 33 of 39 patients with positive HLA-A*02:01 antigen by a pentamer analysis. Conclusion Microtransplantation as a postremission therapy may improve outcomes and avoid GVHD in patients with AML-CR1.

oncology
Impact Of Disease Status On Outcomes Of Allogeneic Hematopietic Stem Cell Transplantation For Refractory Acute Myeloid Leukemia

Qianlan Zhou,XiaoWen Tang,Huiying Qiu,Aining Sun,Changgeng Ruan,Wu Depei

DOI: https://doi.org/10.1182/blood.V120.21.4470.4470

IF: 20.3

2012-01-01

Blood

Abstract:Abstract 4470
Prognostic Factors and Clinical Outcomes in Patients with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Yang Gao,Hengwei Wu,Zhuoyue Shi,Fei Gao,Jimin Shi,Yi Luo,Jian Yu,Xiaoyu Lai,Huarui Fu,Lizhen Liu,He Huang,Yanmin Zhao

DOI: https://doi.org/10.1038/s41409-023-01989-3

2023-01-01

Bone Marrow Transplantation

Abstract:Relapse is a significant barrier to allogeneic hematopoietic stem cell transplantation (allo-HSCT) success. To explore the prognosis of patients who underwent relapse after allo-HSCT, we retrospectively examined 740 consecutive acute leukemia patients in our single center transplanted between January 2013 and December 2018, of which 178 relapsed. The median survival was 204 days (95%CI, 160.7–247.3) from relapse, and the 3-year post-relapse overall survival (prOS) rate was 17.8% (95%CI, 12.5–25.3%). Overall complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 32.1% for the acute myeloid leukemia and 45.3% for acute lymphoblastic leukemia patients after salvage therapy, respectively. Grade III-IV acute graft-versus-host disease (GVHD) after transplantation and >20% bone marrow blasts at relapse were associated with worse prOS, while patients with chronic GVHD after transplantation, relapse later than 1 year after transplantation, and solitary extramedullary disease had better prOS. Therefore, we developed a concise risk scoring system for prOS based on the number of risk factors affecting prOS. This scoring system was validated with another cohort of post-transplant relapsed acute leukemia patients who received allo-HSCT between 2019 and 2020. Identifying relapse risk factors and providing personalized care for patients with poor prognoses is crucial for improving survival.

Extramedullary Relapse Of Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation -Single Center Experience

P1383: Extramedullary Relapse Of Acute Myeloid Leukemia And Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation - A Single-Center Experience

Clinical Characteristics and Outcome of Isolated Extramedullary Relapse in Acute Leukemia Following Allogeneic Stem Cell Transplantation: A Single Institutional Analysis

Extramedullary Relapse of Acute Adult Leukemia Following Allogeneic Stem Cell Transplantation:10 Cases Analysis.

Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

Clinical characteristics and outcome of isolated extramedullary relapse in acute leukemia after allogeneic stem cell transplantation: a single-center analysis.

Haploidentical Allogeneic Hematopoietic Cell Transplantation As Salvage Therapy for Engraftment Failure after Unrelated and Autologous Cell Transplantation.

Clinical Analysis of Extramedullary Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia

Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes.

Extramedullary Relapse Of Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Different Characteristics Between Acute Myeloid Leukemia And Acute Lymphoblastic Leukemia

Extraordinarily Elevated CD33 Expression in CD56+CD3– Cells in the Bone Marrow of a Patient with Relapsed Acute Myeloid Leukemia: a Case Report

Acute Promyelocytic Leukemia With Flt3-Tkd And Wt1 Mutations Relapsing In A Testicle And Followed By Systemic Relapse

High Risk Factors of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-Hsct) for Leukemia.

Comparison of clinical features and treatments of extramedullary relapse after haploidentical and matched sibling donor allogeneic hematopoietic stem cell transplantation in acute leukemia patients

[Extramedullary relapse in the external auditory canal in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid and autologous peripheral blood stem cell transplantation]

Secondary Donor-Derived CD19 CAR-T Therapy is Safe and Efficacious in Acute Lymphoblastic Leukemia with Extramedullary Relapse after First Autologous CAR-T Therapy

Prophylaxis and Treatment of Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

[Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia]

HLA-Mismatched Stem-Cell Microtransplantation As Postremission Therapy for Acute Myeloid Leukemia: Long-Term Follow-Up

Impact Of Disease Status On Outcomes Of Allogeneic Hematopietic Stem Cell Transplantation For Refractory Acute Myeloid Leukemia

Prognostic Factors and Clinical Outcomes in Patients with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation